|
業務類別
|
Biotechnology |
|
業務概覽
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
| 公司地址
| 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 857 259-3860 |
| 傳真號碼
| +1 866 493-4935 |
| 公司網頁
| https://www.scholarrock.com |
| 員工數量
| 289 |
| Ms. Caryn Parlavecchio |
Chief Human Resources Officer |
-- |
22/04/2026 |
| Ms. Junlin Ho, J.D. |
General Counsel and Corporate Secretary |
-- |
22/04/2026 |
| Mr. Robert Keith Woods |
Chief Operating Officer |
美元 523.08K |
22/04/2026 |
| Mr. Vikas Sinha |
Chief Financial Officer and Principal Accounting Officer |
美元 523.08K |
22/04/2026 |
| Ms. Lisa Wyman |
Chief Technical and Quality Officer |
-- |
22/04/2026 |
| Mr. Mohammed Qatanani, PhD |
Chief Scientific Officer |
-- |
22/04/2026 |
| Dr. Akshay K. Vaishnaw, M.D.,PhD |
Director and President, Research and Development |
美元 523.08K |
22/04/2026 |
| Mr. David L. Hallal |
Chairman of the Board and Chief Executive Officer |
美元 637.50K |
22/04/2026 |
| Ms. Rebecca McLeod |
Chief Brand Officer and U.S. General Manager |
-- |
22/04/2026 |
| Dr. Jing L. Marantz, M.D.,PhD |
Chief Medical Officer |
-- |
22/04/2026 |
|
|
| Mr. Joshua Reed |
Independent Director |
22/04/2026 |
| Dr. Jeffrey S. Flier, M.D. |
Independent Director |
22/04/2026 |
| Ms. Kristina M. Burow |
Independent Director |
22/04/2026 |
| Dr. Akshay K. Vaishnaw, M.D.,PhD |
Director and President, Research and Development |
22/04/2026 |
| Mr. Richard H. Brudnick |
Independent Director |
22/04/2026 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
22/04/2026 |
| Mr. David L. Hallal |
Chairman of the Board and Chief Executive Officer |
22/04/2026 |
| Dr. Michael Gilman, PhD |
Independent Director |
22/04/2026 |
| Ms. Katie Peng |
Independent Director |
22/04/2026 |
|
|
|
|
